- July 2016
Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
- June 2016
Key advances in clinical trials.
- May 2016
Mark Lemmon on the underlying biochemistry of cancer.
- April 2016
Roger Stupp on using alternating electric fields as treatment.
- March 2016
Charlotte Vrinten on public perception of deaths from cancer.
- February 2016
Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
- December 2015/January 2016
Nazneen Rahman on germline genetic screening in ovarian cancer.
- November 2015
Caroline Robert on new developments in immunotherapy.
- October 2015
Milena Sant on the latest results from the EUROCARE study.
- September 2015
The science behind the IARC code that could reduce cancer in Europe.
- July/August 2015
Thomas Helleday on an exciting new class of drug, MTH1 inhibitors.
- June 2015
Lesley Seymour and Jan Bogaerts on the future of RECIST.
- May 2015
Paul Workman on strategies for overcoming resistance to new drugs.
- April 2015
Highlights from the TAT Congress in Paris.
- March 2015
Christopher Wild on the exposome, a measure of environmental exposure.
EJC News Focus – June 2013
European Cancer Congress, Amsterdam (27 Sept – 1 Oct)
This autumn, Amsterdam will host the biennial European Cancer Congress with a wide-ranging programme encompassing everything from basic, applied and translational research to practice, treatment, care, prevention and advocacy for cancer patients. This is European oncology's premier multidisciplinary meeting and it will provide a forum for discussion of the latest developments in research and in the clinic.
Key to the congress is dynamic collaboration between specialties: its strapline is 'Reinforcing Multidisiplinarity'. It's a theme close to the heart of co-scientific chair, John Yarnold and here he tells Helen Saul why something we've been talking about for so many years, still needs to be emphasised.